The remarkable success of immune checkpoint inhibitors demonstrates the potential of
tumour-specific CD8+ T cells to prevent and treat cancer. Although the number of lives …

Over the past decade, the emergence of effective immunotherapies has revolutionized the
clinical management of many types of cancers. However, long-term durable tumour control …

Immunotherapy has achieved limited success in patients with triple-negative breast cancer
(TNBC), an aggressive disease with a poor prognosis. Commensal microbiota have been …

Checkpoint inhibitors (CPIs) augment adaptive immunity. Systematic pan-tumor analyses
may reveal the relative importance of tumor-cell-intrinsic and microenvironmental features …

Only a fraction of patients with cancer respond to immune checkpoint blockade (ICB)
treatment, but current decision-making procedures have limited accuracy. In this study, we …

Abstract Treatment with immune checkpoint inhibitors (ICI) has demonstrated clinical benefit
for a wide range of cancer types. Because only a subset of patients experience clinical …

Immune checkpoint inhibitors (ICIs) have yielded remarkable responses but often lead to
immune-related adverse events (irAEs). Although germline causes for irAEs have been …

Clear cell renal cell carcinomas (ccRCCs) are highly immune infiltrated, but the effect of
immune heterogeneity on clinical outcome in ccRCC has not been fully characterized. Here …

Chemotherapy with anti PD-1/PD-L1 antibodies has become the standard of care for
patients with metastatic non-small cell lung cancer (mNSCLC). Using lung tumor models …

Improved identification of anti-tumor T cells is needed to advance cancer immunotherapies.
CD39 expression is a promising surrogate of tumor-reactive CD8+ T cells. Here, we …